Inflammation in Methamphetamine and STIs (IMSTI)

Completed · Not applicable

Conditions studied: Methamphetamine-dependence, Rectal Gonorrhea, Rectal Chlamydia

In brief

This clinical trial aims to investigate the effects of a decline in methamphetamine use on rectal inflammatory cytokine levels, substance use contexts, and HIV/STI risk behavior. This clinical trial also seeks to evaluate joint effects of methamphetamine use and rectal gonorrhea/chlamydia infection on rectal inflammatory cytokine levels. The proposed trial will consist of 40 MSM, half with rectal gonorrhea/chlamydia infection at enrollment (n=20), with methamphetamine use disorder that will receive contingency management for methamphetamine reduction. Following baseline measurement, participants will be observed over the course of 8 weeks, where participants will complete behavioral surveys, provide urine for drug testing, and rectal samples for measurement of rectal inflammatory cytokine levels.

Key facts

Study ID
NCT05162391
Run by
University of California, Los Angeles
People needed
59
Starts
2022-05-31
Expected to finish
2026-04-15
Last updated by the study team
2026-06-11

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.